Crawford Lake Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Crawford Lake Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-60,001	Closed	-$4.66M	–	89
2017 Q4	$4.66M	Buy	+60,001	New	+$4.09M	1.1%	26
2017 Q3	–	Sell	-110,929	Closed	-$5.1M	–	105
2017 Q2	$5.1M	Buy	+110,929	New	+$5.38M	1.13%	26

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Crawford Lake Capital Management's NBIX Position: Q1 2018 in Review

Crawford Lake Capital Management sold out of Neurocrine Biosciences (NBIX) in Q1 2018, closing a stake of 60,001 shares — an estimated $4.66M sold.

Crawford Lake Capital Management first reported a position in NBIX in Q2 2017 and held it in 2 quarters. The position peaked at $5.1M in Q2 2017. 267 funds tracked by Wall St. Rank hold NBIX as of Q1 2018.

Crawford Lake Capital Management reported no remaining Neurocrine Biosciences position as of Q1 2018 after selling out during the quarter.
Crawford Lake Capital Management sold 60,001 Neurocrine Biosciences shares in Q1 2018, an estimated $4.66M.
Crawford Lake Capital Management first reported a position in Neurocrine Biosciences in Q2 2017 and held it in 2 quarters.
Crawford Lake Capital Management's Neurocrine Biosciences position peaked at $5.1M in Q2 2017.
267 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2018.

Based on Crawford Lake Capital Management's 13F filing for Q1 2018, filed 14 May 2018.